Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 3, 2009, Pages 443-452

  Farrell, Geoffrey C ^a   Larter, Claire Z ^a   Hou, Jing Yun ^a   Zhang, Rena H ^b   Yeh, Matthew M ^c   Williams, Jacqueline ^a   Dela Peňa, Aileen ^b   Francisco, Rona ^b   Osvath, Sarah R ^b   Brooling, John ^a   Teoh, Narcissus ^a   Sedger, Lisa M ^b  

^a CANBERRA HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Cell death pathways; Insulin like growth factor 1; Methionine and choline deficiency; Mitochondria; P53; TNF receptors; TRAIL R killer DR5

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CHOLINE; FAS ANTIGEN; MESSENGER RNA; METHIONINE; PROTEIN BCL XL; PROTEIN BID; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HEPATITIS; HISTOPATHOLOGY; LIVER INJURY; MALE; MOUSE; NICK END LABELING; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 63049134573     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05785.x     Document Type: Article

References (39)

1. Farrell GC, Larter CZ. Non-alcoholic fatty liver disease. From steatosis to cirrhosis. Hepatology 2006 43 (Suppl. 1 S1 12.
2. Feldstein AE, Canbay A, Angulo P et al. Hepatocyte apoptosis and Fas expression are prominent features of human non-alcoholic steatohepatitis. Gastroenterology 2003 125 : 437 43.
3. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas-mediated liver injury in mice. J. Hepatol. 2003 39 : 978 83.
4. Kaplowitz N, Ji C. Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum. J. Gastroenterol. Hepatol. 2006 21 : S7 9.
5. Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D. Expression of p53, Bax and Bcl-2-proteins in hepatocytes in non-alcoholic fatty liver disease. World J. Gastroenterol. 2006 12 : 6198 202.
6. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006 44 : 27 33.
7. Ribeiro PS, Cortez-Pinto H, Sola S et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 2004 99 : 1708 17.
8. Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006 43 : 163 72.
9. Zou C, Ma J, Wang X et al. Lack of Fas antagonism by Met in human fatty liver disease. Nat. Med. 2007 13 : 1078 85.
10. Kleiner DE, Brunt EM, van Natta M et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005 41 : 1313 21.
11. Kirsch R, Clarkson V, Shephard EG et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 2003 18 : 1272 82.
12. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB activation rather than TNF mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005 129 : 1663 74.
13. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004 39 : 1286 96.
14. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grosse RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001 48 : 206 11.
15. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005 54 : 303 6.
16. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J. Hepatol. 2006 44 : 253 61.
17. Hui J, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004 40 : 19 22.
18. Memon RA, Grunfeld C, Feingold KR. TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat. Med. 2001 7 : 2 3.
19. Deng QG, She H, Cheng J et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005 42 : 905 14.
20. Mundt B, Wirth T, Zender L et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005 54 : 1590 6.
21. Volkmann X, Fischer U, Bahr MJ et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007 46 : 1498 508.
22. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006 43 (Suppl. 1 S31 44.
23. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 2004 113 : 58 64.
24. Hao C, Song JH, Hsi B et al. TRAIL inhibits tumor growth but is non-toxic to human hepatocytes in chimeric mice. Cancer Res. 2004 64 : 8502 6.
25. Sedger LM, Glaccum MB, Schuh JCL et al. Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 2002 32 : 2246 54.
26. Sedger LM, Shows DM, Blanton RA et al. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 1999 163 : 920 6.
27. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007 56 : 1124 31.
28. Matzinger P. The danger model: a renewed sense of self. Science 2002 296 : 301 5.
29. Yahagi N, Shimano H, Matsuzaka T et al. p53 involvement in the pathogenesis of fatty liver disease. J. Biol. Chem. 2004 279 : 20571 5.
30. Kasten MB. Wild-type p53: tumors can't stand it. Cell 2007 128 : 837 40.
31. Rizki G, Arnaboldi L, Gabrielli B et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J. Lipid. Res. 2006 47 : 2280 90.
32. Larter CZ, Yeh MM, Haigh WG et al. Adaptive mechanisms to hepatic lipid accumulation in steatohepatitis fail to prevent free fatty acid accumulation. J. Hepatol 2008 48 : 638 47.
33. Wu GS, Burns TF, McDonald ER et al. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 1999 18 : 6411 18.
34. Thissen JP, Pucilowska JB, Underwood LE. Differential regulation of insulin-like growth factor I (IGF-I) and IGF binding protein-1 messenger ribonucleic acids by amino acid availability and growth hormone in rat hepatocyte primary culture. Endocrinology 1994 134 : 1570 6.
35. Hursting SD, Perkins SN, Phang JM, Barrett JC. Diet and cancer prevention studies in p53-deficient mice. J. Nutr. 2001 131 : 3092S 4S.
36. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gorest GJ. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 2004 279 : 51 60.
37. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 2006 281 : 12093 101.
38. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 2007 17 : 493 503.
39. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 2008 23 : 1635 48.